AMY-101 TFA

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 ( K D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation In Vivo AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis . AMY-101 can induce a long-lasting anti-inflammatory effect . AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction . AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight) . Dosage: 0.1 mg/site; 50 μL of 2 mg/mL solution. Administration: Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.) Result: Does not cause irritation in healthy gingiva. Animal Model: UUO and sham-operated mice. Dosage: 1 mg/kg. Administration: Subcutaneous injection every 12 h, daily, 7 or 14 days. Result: 1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice. Form:Solid IC50& Target:KD: 0.5 nM (C3)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet